PT  - JOURNAL ARTICLE
AU  - Wood, Helen E.
AU  - Kalsi, Harpal
AU  - Cross, Louise
AU  - Dove, Rosamund E.
AU  - Scales, James
AU  - Tsocheva, Ivelina
AU  - Chavda, Jasmine
AU  - Colligan, Grainne
AU  - Lie, Esther
AU  - Petrovic, Kristian
AU  - Tomini, Florian
AU  - Tofolutti, Veronica
AU  - Day, Bill
AU  - Keighley, Amanda
AU  - Critchlow, Cheryll
AU  - Beevers, Sean
AU  - Fletcher, Monica
AU  - Gauderman, W. James
AU  - Grigg, Jonathan
AU  - Mihaylova, Borislava
AU  - Newby, Chris
AU  - van Sluijs, Esther
AU  - Kelly, Frank
AU  - Sheikh, Aziz
AU  - Randhawa, Gurch
AU  - Mudway, Ian S.
AU  - Griffiths, Chris J.
TI  - Investigating the impact of London’s Ultra Low Emission Zone (ULEZ) on children’s health: cohort description and baseline data from the Children’s Health in London and Luton (CHILL) prospective parallel cohort study
AID  - 10.1101/2024.06.05.24308482
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.06.05.24308482
4099  - http://medrxiv.org/content/early/2024/06/05/2024.06.05.24308482.short
4100  - http://medrxiv.org/content/early/2024/06/05/2024.06.05.24308482.full
AB  - Traffic-related air pollution (TRAP) poses significant health risks particularly for children, with adverse effects that may impact health in later life. Low emission zones are a public health policy designed to reduce TRAP in urban areas.The CHILL (Children’s Health in London and Luton) Study will evaluate the impact of London’s Ultra Low Emission Zone (ULEZ) on children’s health, using a prospective two-arm parallel longitudinal cohort design. CHILL will examine associations between air pollution metrics and lung function growth, plus secondary outcomes. Here we describe the characteristics of the CHILL cohort at baseline, prior to the introduction of the ULEZ.We recruited 3414 children aged 6-9 years attending 84 schools (London – intervention site: 1664 children, 44 schools; Luton – comparator site: 1750 children, 40 schools). Baseline health assessments were conducted in 2018-2019 (before the introduction of the ULEZ in London). 97.0% of recruited children were assessed (London 96.5%, Luton 97.4%), with the primary outcome measure of post-bronchodilator forced expiratory volume in one second being successfully measured in 76.7% (London 76.9%, Luton 76.5%). 92.1% returned a completed parental questionnaire (London 89.3%, Luton 94.7%), including data for analysis of the secondary outcomes. Demographic characteristics and outcomes were similar across the two sites.We established well-matched cohorts of school children, in our intervention (London) and comparator (Luton) sites. Data on primary and secondary outcomes have been successfully collected, which, combined with detailed air quality metrics, provides a robust platform for evaluating the impact of London’s ULEZ on children’s health and development.ClinicalTrials.gov NCT04695093 (05/01/2021)Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://pubmed.ncbi.nlm.nih.gov/37925402/ Funding StatementThis study was supported by the National Institute of Health Research Public Health Research (grant number 16/139/09) with additional funding by NIHR CLAHRC North Thames, Barts Charity, and NIHR ARC North Thames. EvS is funded by the Medical Research Council [MC UU 00006/5]. BM acknowledges support by the National Institute for Health Research Barts Biomedical Research Centre (NIHR203330). CJG is supported by the NIHR ARC North Thames. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Funders played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Queen Mary University of London Research Ethics Committee (ref 2018/08) and NHS West of Scotland Research Ethics Committee 4 (reference 22/WS/0065) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors